apparent on the original visit. She came with a family member who reported sudden onset and rapid worsening of the patient's cognition with new issues of confusion and disorientation. Short-term memory was poor, but long-term memory remained intact. Mini-Mental Status Examination yielded 2 out of 3 correct for recall. Hyperhidrosis was more prominent occurring during wakefulness hours as well as during sleep.
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The patient's sleep-wake schedule was erratic with intermittent brief dozing day and night. Her sleep behaviors, such as dressing herself, combing her hair, and tying her shoes, were more complex. Initially dream enactment behaviors were simpler with calling out and sitting up in bed. She was unresponsive during these periods, amnestic for her actions in sleep, but awoke oriented. Despite efforts to use PAP, the patient would disassemble her interface while asleep. She reported horizontal diplopia, new-action tremor, and a 12-lb weight loss. Her pertinent vital signs were blood pressure 164/108 and heart rate 110 bpm. Comprehensive metabolic panel, thyroid function tests, urinalysis, and head computed tomography were unrevealing. Repeat PSG was attempted on continuous positive airway pressure with the patient demonstrating little sleep ( Table 1) .
A 51-year-old woman presented with insomnia for 2 months and daytime sleepiness for 6 months. The patient attributed the insomnia to stress from recent life events. Her Epworth Sleepiness Scale score was 18 of 24. Observers of the patient reported loud snoring, apneas, kicking, and dream enactment. The patient had hyperhidrosis during sleep.
Family history was positive for hypertension and dementia. Social history excluded tobacco, alcohol, or illicit drug usage. Review of symptoms was significant for heart palpitations, headaches, and depression. The patient's medical history was negative with no medications.
Physical examination revealed a blood pressure of 140/90 and body mass index of 30.3 kg/m 2 . The patient's Mallampati score was class IV. Physical examination was otherwise unremarkable. Neurological examination showed normal reflexes, gait, and intellect with good recent and remote memory recall.
Diagnostic polysomnography (PSG) showed apnea-hypopnea index, 84.4 events/h; periodic limb movement index, 10.7 events/h; reduced total sleep time (140 minutes); increased stage N1 sleep; and no stage N3 or R sleep. Minimum oxygen saturation was 80%. Sleep spindles were absent.
The patient refused an in-laboratory positive airway pressure (PAP) titration, and was placed on auto-adjusting PAP therapy for her severe obstructive sleep apnea.
At FFI is a prion disease with autosomal dominant inheritance of mutation in the prion gene PRNP. 1 Symptoms usually appear between ages 32 and 62 years with unrelenting insomnia, poor appetite, weight loss, temperature dysregulation, and dementia. 1 The initial symptom is sometimes dementia, not insomnia. Autonomic manifestations can include hyperventilation, hyperhidrosis, hypertension, tachycardia, and excessive drooling. 2 Our patient also presented with hyperhidrosis, loss of sleep spindles, and sleep-disordered breathing similar to signs and symptoms noted in the series by Wu et al. 3 With disease progression ataxia, hallucinations, delirium, and myoclonus may develop. Initial confusion and forgetfulness progress to aphasia or immobility with eventual total inability to sleep with end-stage FFI. 1 Additional supporting history includes a family history of unexplained dementia occurring at a young age.
Evaluation includes PSG and positron emission tomography (PET) scanning to confirm thalamic hypometabolism.
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Genetic testing in the United States is available if 1 of 3 criteria are met (family history of FFI, abnormal PSG or PET scan with high suspicion for FFI, diagnosis of FFI by PSG and PET scan). 1 Genetic evaluation examines for a mutation at codon 178 on chromosome 20, resulting in an asparagine instead of aspartic acid combined with a methionine codon at position 129.
Currently there is no cure or effective treatment for FFI. The prognosis is poor, with death occurring in 12 to 72 months (range, a few months to several years). 2 In our patient, a PET scan confirmed decreased thalamic activation. Genetic testing showed the D178N-129M mutated allele in the prion protein gene linked to FFI. The patient died 10 months after symptom onset. Her daughter (age 35 years), son (age 30 years), and cousin tested positive for the FFI gene. 
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